Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research - 1 Mar 2010

Frost Morten, Andersen Tom Erenskjold, Yadav Vijay, Brixen Kim, Karsenty Gerard, Kassem Moustapha

Abstract excerpt

The Lrp5 gene is a major determinant of bone mass accrual. It has been demonstrated recently to achieve this function by hampering the synthesis of gut-derived serotonin, which is a powerful inhibitor of bone formation. In this study we analyzed plasma serotonin levels in patients with a high-bone-mass (HBM) phenotype owing to gain-of-function mutation of Lrp5 (T253I). A total of 9 HBM patients were compared with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Density
Share to LDL-Receptor Related Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Low Density Lipoprotein Receptor-Related Protein-5

Share to Mutation

Share to Osteogenesis

Share to Phenotype

Share to Serotonin

Source

Identifiers

PMID: 20200960
DOI: 10.1002/jbmr.44

Genes

HBM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin.PMID 20200960Read ↗

Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5.Semantic proximity Read ↗

Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5.Semantic proximity Read ↗

LRP5 and bone mass regulation: Where are we now?Semantic proximity Read ↗

Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.Semantic proximity Read ↗

Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia.Semantic proximity Read ↗

No mutations in the serotonin related TPH1 and HTR1B genes in patients with monogenic sclerosing bone disorders.Semantic proximity Read ↗

Efficacy of serotonin inhibition in mouse models of bone loss.Semantic proximity Read ↗

Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.Semantic proximity Read ↗

Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells.Semantic proximity Read ↗

Lrp5 functions in bone to regulate bone mass.Semantic proximity Read ↗

The LRP5 high-bone-mass mutation causes alveolar bone accrual with minor craniofacial alteration.Semantic proximity Read ↗

High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.